Postdoctoral Research Fellow

Job description

  Job facts

We are seeking an independent and motivated researcher for a postdoctoral position. Candidates with a strong background in cancer biology, immunology, or vascular biology are a good fit for this position.

The successful candidate will join a research team that investigates vascular development, control of anti-tumor immune response by tumor vasculature, regulation of peripheral tolerance by lymphatics, and influence of dying cell clearance on the induction of anti-tumor immunogenicity.

Selected publications from the Yan lab:

·  Gu Zhang, John Brady, Wei-Ching Liang, Yan Wu, Mark Henkemeyer, and Minhong Yan. EphB4 forward signaling regulates lymphatic valve development. Nature Communications 2015; 6:6625.
·  Hao Chen, John Brady Ridgway, Tao Sai, Joyce Lai, Søren Warming, Hanying Chen, Merone Roose-Girma, Gu Zhang, Weinian Shou, and Minhong Yan. Context-dependent signaling defines roles of BMP9 and BMP10 in embryonic and postnatal development PNAS 2013 110 (29):11881-11892.
·  Niessen K, Zhang G, Ridgway JB, Chen H, Kolumam G, Siebel CW, and Yan M. The Notch1-DLL4 signaling pathway regulates mouse postnatal lymphatic development Blood 2011; 118(7):1989-1997
·  Yan M, Callahan CA, Beyer, JC, Allamneni KP, Zhang G, Ridgway JB, Niessen K, Plowman GD. Chronic DLL4 blockade induces vascular neoplasms Nature 2010; 463, E6-E7.
·  Niessen K, Zhang G, Ridgway JB, Chen H, and Yan M*. ALK1 signaling regulates early postnatal lymphatic vessel development Blood 2010; 115(8):1654-1661.
·  Ridgway J, Zhang G, Wu Y, Stawicki S, Liang W, Chanthery Y, Kowalski J, Watts RJ, Callaha C, Kasman I, Singh M, Chien M, Tan C, Hongo J, De Sauvage F, Plowman G, Yan M. Blocking of Dll4 signaling inhibits tumour growth by deregulating angiogenesis. Nature 2006; 444:1083-87. For more information on Minhong Yan's lab, please visit http://www.gene.com/scientists/our-scientists/minhong-yan

For information about the Postdoctoral Program at Genentech, please go to www.gene.com/careers/academic-programs/postdocs

·  Who we are

A member of the Roche Group, Genentech has been at the forefront of the biotechnology industry for more than 40 years, using human genetic information to develop novel medicines for serious and life-threatening diseases. Genentech has multiple therapies on the market for cancer & other serious illnesses. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.

Roche is an equal opportunity employer and strictly prohibits unlawful discrimination based upon an individual's race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, mental/physical disability, medical condition, marital status, veteran status, or any other characteristic protected by law.

Desired profile

Who you are

You're someone who wants to influence your own development. You're looking for a company where you have the opportunity to pursue your interests across functions and geographies. Where a job title is not considered the final definition of who you are, but the starting point.
The candidate should have a Ph.D. degree with a strong background in cancer biology, immunology, or vascular biology. Qualification should be clearly demonstrated by at least one first author paper published or accepted in a high-quality journal.

*LI-gRED-RR
·